Exploring the Feasibility of Comprehensive Uncertainty Assessment in Health Economic Modeling: A Case Study.

OBJECTIVES Decision makers adopt health technologies based on health economic models that are subject to uncertainty. In an ideal world, these models parameterize all uncertainties and reflect them in the cost-effectiveness probability and risk associated with the adoption. In practice, uncertainty assessment is often incomplete, potentially leading to suboptimal reimbursement recommendations and risk management. This study examines the feasibility of comprehensive uncertainty assessment in health economic models. METHODS A state transition model on peripheral arterial disease treatment was used as a case study. Uncertainties were identified and added to the probabilistic sensitivity analysis if possible. Parameter distributions were obtained by expert elicitation, and structural uncertainties were either parameterized or explored in scenario analyses, which were model averaged. RESULTS A truly comprehensive uncertainty assessment, parameterizing all uncertainty, could not be achieved. Expert elicitation informed 8 effectiveness, utility, and cost parameters. Uncertainties were parameterized or explored in scenario analyses and with model averaging. Barriers included time and resource constraints, also of clinical experts, and lacking guidance regarding some aspects of expert elicitation, evidence aggregation, and handling of structural uncertainty. The team's multidisciplinary expertise and existing literature and tools were facilitators. CONCLUSIONS While comprehensive uncertainty assessment may not be attainable, improvements in uncertainty assessment in general are no doubt desirable. This requires the development of detailed guidance and hands-on tutorials for methods of uncertainty assessment, in particular aspects of expert elicitation, evidence aggregation, and handling of structural uncertainty. The issue of benefits of uncertainty assessment versus time and resources needed remains unclear.

[1]  David Moher,et al.  Consolidated Health Economic Evaluation Reporting Standards (CHEERS)--explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. , 2013, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[2]  D. Spiegelhalter,et al.  Disease Mapping With WinBUGS and MLwiN, Bayesian Approaches to Clinical Trials and Health Care Evaluation , 2004 .

[3]  Khalid Yusoff,et al.  Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. , 2017, Lancet.

[4]  Ken Stein,et al.  Informing Reimbursement Decisions Using Cost-Effectiveness Modelling: A Guide to the Process of Generating Elicited Priors to Capture Model Uncertainties , 2017, PharmacoEconomics.

[5]  K. Payne,et al.  Reporting Guidelines for the Use of Expert Judgement in Model-Based Economic Evaluations , 2016, PharmacoEconomics.

[6]  Philippe Beutels,et al.  Accounting for Methodological, Structural, and Parameter Uncertainty in Decision-Analytic Models , 2011, Medical decision making : an international journal of the Society for Medical Decision Making.

[7]  Ken Stein,et al.  EXPLICIT: a feasibility study of remote expert elicitation in health technology assessment , 2017, BMC Medical Informatics and Decision Making.

[8]  Mark Strong,et al.  Computing the Expected Value of Sample Information Efficiently: Practical Guidance and Recommendations for Four Model-Based Methods. , 2020, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[9]  David Schultz,et al.  A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) , 1996, The Lancet.

[10]  W. Walker,et al.  Defining Uncertainty: A Conceptual Basis for Uncertainty Management in Model-Based Decision Support , 2003 .

[11]  M. Joore,et al.  Comparison of three generic quality-of-life metrics in peripheral arterial disease patients undergoing conservative and invasive treatments , 2019, Quality of Life Research.

[12]  H. V. van Stel,et al.  Impact of secondary cardiovascular events on health status. , 2012, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[13]  Karl Claxton,et al.  Exploring Uncertainty in Cost-Effectiveness Analysis , 2012, PharmacoEconomics.

[14]  Elisabeth Fenwick,et al.  Value of Information Analytical Methods: Report 2 of the ISPOR Value of Information Analysis Emerging Good Practices Task Force. , 2020, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[15]  Karl Claxton,et al.  Eliciting distributions to populate decision analytic models. , 2010, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[16]  M. Hunink,et al.  Cost-effectiveness of endovascular revascularization compared to supervised hospital-based exercise training in patients with intermittent claudication: a randomized controlled trial. , 2008, Journal of vascular surgery.

[17]  Salah Ghabri,et al.  Towards a New Framework for Addressing Structural Uncertainty in Health Technology Assessment Guidelines , 2018, PharmacoEconomics.

[18]  M. Prins,et al.  Cost-effectiveness of exercise therapy in patients with intermittent claudication: supervised exercise therapy versus a 'go home and walk' advice. , 2011, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

[19]  M. Sculpher,et al.  Health Opportunity Costs: Assessing the Implications of Uncertainty Using Elicitation Methods with Experts , 2020, Medical decision making : an international journal of the Society for Medical Decision Making.

[20]  Erik Lebret,et al.  The use of expert elicitation in environmental health impact assessment: a seven step procedure , 2010, Environmental health : a global access science source.

[21]  Andrew Briggs,et al.  An Introduction to Markov Modelling for Economic Evaluation , 1998, PharmacoEconomics.

[22]  John Paul Gosling,et al.  SHELF: The Sheffield Elicitation Framework , 2018 .

[23]  Mark Strong,et al.  The HTA Risk Analysis Chart: Visualising the Need for and Potential Value of Managed Entry Agreements in Health Technology Assessment , 2017, PharmacoEconomics.

[24]  Jeremy E. Oakley,et al.  Probability is perfect, but we can't elicit it perfectly , 2004, Reliab. Eng. Syst. Saf..

[25]  William Hollingworth,et al.  Model Transparency and Validation , 2012, Medical decision making : an international journal of the Society for Medical Decision Making.

[26]  A. Algra,et al.  Cost-effectiveness of oral anticoagulants versus aspirin in patients after infrainguinal bypass grafting surgery. , 2001, Journal of vascular surgery.

[27]  M. Joore,et al.  Rivaroxaban plus aspirin for the prevention of ischaemic events in patients with cardiovascular disease: a cost-effectiveness study , 2020, European journal of preventive cardiology.

[28]  Christopher James Sampson,et al.  Model Registration: A Call to Action , 2017, PharmacoEconomics - Open.

[29]  D. Clement A randomised, blinded, trial of Clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) , 1996 .

[30]  Jonathan Karnon,et al.  Model Parameter Estimation and Uncertainty Analysis , 2012, Medical decision making : an international journal of the Society for Medical Decision Making.

[31]  Sean Ekins,et al.  Time for Cooperation in Health Economics among the Modelling Community , 2012, PharmacoEconomics.

[32]  F. Hamers,et al.  Exploring Uncertainty in Economic Evaluations of Drugs and Medical Devices: Lessons from the First Review of Manufacturers’ Submissions to the French National Authority for Health , 2016, PharmacoEconomics.

[33]  Jeremy E. Oakley,et al.  Managing structural uncertainty in health economic decision models: a discrepancy approach , 2012 .

[34]  Andrew R Willan,et al.  Optimal clinical trial design using value of information methods with imperfect implementation. , 2009, Health economics.

[35]  Jeremy E. Oakley,et al.  Estimating Multiparameter Partial Expected Value of Perfect Information from a Probabilistic Sensitivity Analysis Sample , 2013, Medical decision making : an international journal of the Society for Medical Decision Making.

[36]  J. Bosch,et al.  Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. , 2018, Lancet.

[37]  Kerrie Mengersen,et al.  Characterising Uncertainty in Expert Assessments: Encoding Heavily Skewed Judgements , 2015, PloS one.

[38]  Karl Claxton,et al.  Characterizing structural uncertainty in decision analytic models: a review and application of methods. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[39]  Saskia Knies,et al.  Development and Validation of the TRansparent Uncertainty ASsessmenT (TRUST) Tool for Assessing Uncertainties in Health Economic Decision Models , 2019, PharmacoEconomics.

[40]  Manuela A. Joore,et al.  Healthy Decisions: Towards Uncertainty Tolerance in Healthcare Policy , 2014, PharmacoEconomics.

[41]  A. Algra,et al.  Statin treatment for primary prevention of vascular disease: whom to treat? Cost-effectiveness analysis , 2011, BMJ : British Medical Journal.

[42]  M. Sculpher,et al.  Catalogue of EQ-5D Scores for the United Kingdom , 2011, Medical decision making : an international journal of the Society for Medical Decision Making.

[43]  Karl Claxton,et al.  Experiences of Structured Elicitation for Model-Based Cost-Effectiveness Analyses , 2018, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[44]  M L Simoons,et al.  Cost-effectiveness of HMG coenzyme reductase inhibitors; whom to treat? , 2001, European heart journal.